328.F MEIRAGTX HLDGSDL-0000388

Healthcare Biotechnology Frankfurt Exchange
8.65 EUR
Close of Nov 11, 2026
5.85 13.10
Market cap
EUR 831M
P/E
11.5x
P/B
4.27x
ROE
106.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 328.F undervalued?

Graham number
Price8.65
Graham value5.84
Premium48.0%

328.F trades 48.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MEIRAGTX HLDGSDL-0000388 fundamental analysis

No fundamental analysis for MEIRAGTX HLDGSDL-0000388 yet.

MEIRAGTX HLDGSDL-0000388 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MEIRAGTX HLDGSDL-0000388

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkin…

Full company profile